BEAM [carmustine, etoposide, cytarabine and melphalan] + 131Iodine-Anti-B1 [iodine-131-tositumomab] radioimmunotherapy and autologous hematopoietic stem cell transplantation [HSCT] for the treatment of recurrent non-hodgkin's lymphoma.
Phase of Trial: Phase I
Latest Information Update: 08 May 2017
At a glance
- Drugs Iodine-131 tositumomab (Primary) ; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Melphalan
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 01 May 2017 Status changed from active, no longer recruiting to completed.
- 09 Jan 2008 New trial record.